BeOne Medicines is delivering strong oncology growth, led by BRUKINSA and expanding TEVIMBRA sales. The stock earns a Buy, but a premium valuation and product concentration keep the risk profile elevated.
BeiGene, Ltd., now operating as BeOne Medicines under Nasdaq ticker ONC, merits a Buy rating for a moderate-risk investor with a medium-term horizon. The investment case rests on a profitable commercial oncology business, BRUKINSA's leading position in BTK inhibition, expanding TEVIMBRA sales, and a pipeline that is moving several assets toward pivotal development.
The operating evidence is strong. Q2 2026 revenue reached $1.7B, up 30% year over year, while GAAP earnings per ADS rose 144% to $2.05. Management raised 2026 revenue guidance to $6.6B to $6.8B and GAAP operating income guidance to $1.0B to $1.1B. BRUKINSA generated more than $1.2B in global Q2 revenue, up 31%.
The risk is valuation and concentration. ONC trades at 73.9x trailing earnings and 47.8x forward earnings, while BRUKINSA remains the primary commercial engine. The company also faces large-cap competitors in PD-1 therapy and BTK inhibition, China-related operating exposure, patent risk, and a mixed recent earnings record of four beats in seven reported quarters.
The balance sheet provides room to fund clinical development. At December 31, 2025, ONC held $4.55B of cash against $1.10B of debt, a 3.4 current ratio, and 0.25 debt-to-equity. That financial cushion makes the company less dependent on external capital than a typical development-stage biotech.
BeOne Medicines is a global oncology company founded in 2010 with approximately 12,000 employees. The company changed its name from BeiGene in May 2025. It operates across the United States, China, Europe, Japan, Brazil, and other international markets, with commercial products led by BRUKINSA and TEVIMBRA.
BRUKINSA is zanubrutinib, a small-molecule BTK inhibitor used in B-cell malignancies. TEVIMBRA is tislelizumab, an anti-PD-1 antibody used across solid tumors and hematologic cancers. The company also markets or is advancing products and programs including BEQALZI, sonrotoclax, a BTK degrader, ADCs, bispecific antibodies, and targeted small molecules.
The company has built a commercial-and-R&D model rather than relying solely on early clinical assets. In 2025, annual revenue reached $5.34B, compared with $1.18B in 2021. Operating income turned positive at $447.1M in 2025 after losses in each of the prior four years.
ONC also has collaboration and licensing relationships with Amgen, Bristol Myers Squibb, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The Amgen in-licensed portfolio generated $157M of Q2 2026 revenue, up 25% year over year.
ONC presents its business mainly by product and geography rather than as a set of traditional operating segments. The Q2 2026 product mix shows a clear hierarchy: BRUKINSA produced more than $1.2B of global revenue, TEVIMBRA produced $229M, and the Amgen portfolio produced $157M.
Geographic revenue was broad in Q2. The United States contributed approximately $899M and grew 31% year over year. China contributed approximately $500M and grew 17%, Europe contributed approximately $208M and grew 37%, and rest-of-world revenue more than doubled to approximately $73M.
The United States is now the largest growth and profit center, while China remains strategically important for TEVIMBRA and BRUKINSA. Europe and rest-of-world markets add diversification, with Japan and Brazil becoming more meaningful contributors at the enterprise level.
The product mix is favorable because the two principal internal products carry high gross margins and support continued operating leverage. Q2 gross profit was $1.5B, with gross margin just under 90%, while operating expenses rose 13%, slower than the 30% increase in revenue.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
BRUKINSA is the central asset in the ONC thesis. Management reported Q2 global revenue above $1.2B, up 31% year over year, and U.S. sales of $893M, also up 31%. The product has approvals in five B-cell malignancies and has treated more than 300,000 patients across more than 80 markets.
The clinical record supports the commercial position. In the ALPINE head-to-head trial against ibrutinib, BRUKINSA delivered a progression-free survival hazard ratio of 0.69, with separation sustained at a median follow-up of 42.5 months. Management also cited six-year landmark progression-free survival of 70% for BRUKINSA in unmutated IGHV patients, compared with 42% for the venetoclax-obinutuzumab regimen it referenced.
Commercial momentum is not limited to CLL. Management reported the highest sustained level of new patient starts since launch, growth across all five approved indications, and improved adherence after the tablet formulation reduced pill size and treatment burden late in 2025.
TEVIMBRA is the second commercial pillar. Q2 global sales reached $229M, up 18% year over year, and the product retained market leadership in China despite steep competition. Its global opportunity expands through additional indications and combination programs, including the HER2-positive gastroesophageal adenocarcinoma application involving ZIIHERA and chemotherapy.
ONC's strongest competitive advantage is the combination of commercial scale and internal pipeline depth. Management describes BRUKINSA as having the largest body of reported and ongoing Phase III data among BTK inhibitors, with four additional potentially market-expanding Phase III readouts over the next three years.
The company is also building a broader hematology franchise. BEQALZI received FDA approval as a BCL-2 inhibitor for relapsed or refractory mantle cell lymphoma. Tacabrutideg is advancing in potentially registrational Phase II studies, while the Phase III CaDAnCe-304 study compares the BTK degrader with pirtobrutinib in relapsed or refractory CLL.
The solid-tumor pipeline is becoming more diversified. BGB-43395, a CDK4 inhibitor, reported an objective response rate of around 70% with letrozole in first-line HER2-negative metastatic breast cancer. At the 400 milligram dose, overall neutropenia was 21% with no grade 3 or higher events.
Other proof-of-concept assets include BGB-B2033, a GPC3 x 4-1BB bispecific with an objective response rate above 30% in second-line or later hepatocellular carcinoma, and BG-C9074, a B7-H4 ADC with approximately 26% treatment-related grade 3 or higher adverse events at 6 milligrams per kilogram. The company has said five solid-tumor programs have reached clinical proof of concept and are moving toward pivotal development.
ONC is expanding its manufacturing footprint as commercial demand grows. Management announced a $300M expansion of its flagship U.S. manufacturing site in Hopewell, New Jersey. That investment supports greater U.S. production capacity, although it also adds construction and execution requirements to an already broad global operating model.
The company generated $185.8M of capital expenditures in 2025, well below the $529.1M spent in 2024. Q1 2026 capital expenditures were $40.9M, while free cash flow was $161.0M. These figures show that recent commercial growth has not required a comparable increase in capital intensity.
Manufacturing economics are supported by high product margins. Q2 gross margin was just under 90%, and management maintained a full-year gross-margin outlook in the high-80% range. Management also guided 2026 operating expenses to $4.8B to $5.0B as the company funds commercial expansion and clinical development.
The supply chain must serve approvals in 77 markets for BRUKINSA and 51 markets for TEVIMBRA, according to company materials. That footprint increases manufacturing scale benefits but creates exposure to regulatory, logistics, quality-control, and country-specific distribution requirements.
The broader biotechnology market remains large and expanding. Grand View Research estimates a $1.55T global biotechnology market in 2024 and $3.88T by 2030, implying a 14.0% compound annual growth rate. That figure covers much more than oncology medicines, so ONC's monetizable market is narrower and centers on hematology, solid tumors, and related supportive therapies.
ONC has positioned itself in two large oncology categories. BTK inhibition addresses B-cell malignancies, while PD-1 therapy addresses a wide range of solid tumors and blood cancers. BRUKINSA's five approved indications and TEVIMBRA's approvals in 51 markets give the company multiple routes to expand within those categories.
The market is also shifting toward differentiated modalities. Industry materials identify bispecific antibodies, ADCs, cell therapies, and gene therapies as important areas of oncology development. ONC's pipeline includes bispecifics, ADCs, degraders, and targeted inhibitors, aligning the company with those technology shifts rather than relying exclusively on conventional antibody development.
The commercial test is more demanding than the market-size figures suggest. ONC must translate clinical differentiation into physician adoption, reimbursement, treatment duration, and durable market share. Q2 revenue growth of 30% and BRUKINSA growth of 31% show that the company is currently converting its opportunity into reported sales.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
ONC's direct commercial customers are oncology prescribers, hospitals, specialty pharmacies, and distribution partners. Management said prescribers increasingly selected BRUKINSA because of its efficacy, durability data, and real-world experience. More than 300,000 patients have received BRUKINSA across more than 80 markets, giving the product a substantial treatment history.
The customer base is geographically diversified but economically concentrated in the United States, China, and Europe. Q2 revenue of approximately $899M in the United States, $500M in China, and $208M in Europe confirms the importance of those three markets.
Treatment convenience is becoming part of the customer proposition. Management linked improved adherence to the BRUKINSA tablet formulation, which reduced pill size and burden. In oncology, a product's clinical profile and its practical use both influence treatment selection, and the tablet update gives the commercial team another concrete point of differentiation.
The 2025 annual filing identifies McKesson, Shanghai Pharmaceutical, and ADS Specialty Healthcare in its customer concentration disclosures. Those relationships make distribution execution important, although the company also has a broad international commercial infrastructure rather than a single-market sales model.
BRUKINSA competes with ibrutinib, acalabrutinib, and pirtobrutinib in BTK inhibition. Management cited a hazard ratio of 0.69 for BRUKINSA versus ibrutinib in ALPINE, a final hazard ratio of 1.0 for acalabrutinib versus ibrutinib in ELEVATE-RR, and a hazard ratio of 0.845 for pirtobrutinib versus ibrutinib in BRUIN-314.
Those comparisons support BRUKINSA's clinical positioning, but cross-trial comparisons remain imperfect. Differences in patient eligibility, follow-up duration, and adverse-event reporting can affect apparent differences between products. ONC's advantage is strongest where its head-to-head and long-term data directly support treatment durability.
TEVIMBRA competes against entrenched PD-1 and PD-L1 products including Keytruda, Opdivo, Tecentriq, Imfinzi, Bavencio, Libtayo, and Jemperli. These competitors belong to companies with significantly larger oncology portfolios and broader financial resources. TEVIMBRA's 18% Q2 growth and market leadership in China show traction, but the category remains crowded.
ONC's competitive position is therefore stronger than that of a typical development-stage biotech but smaller than that of Merck, Bristol Myers Squibb, Roche, AstraZeneca, or Johnson & Johnson. Its advantage comes from focused oncology execution, global commercialization, and a deep internal pipeline rather than from portfolio breadth across every therapeutic area.
ONC has meaningful exposure to China and the broader relationship between China, the United States, and Europe. The 2025 annual filing identifies risks related to operating in the PRC, including regulatory conditions and potential restrictions affecting cash flows from Chinese subsidiaries.
Currency also affects reported growth. Management said foreign exchange contributed 7% of Q2 reported growth because of year-over-year renminbi strengthening. That contribution can move in the opposite direction in another reporting period, creating a source of volatility even when underlying product demand remains steady.
Regulatory and pricing pressure are structural features of oncology. FDA materials cite 76 approved biosimilars and continued efforts to lower biologic treatment costs. While biosimilar pressure does not directly determine BRUKINSA's current position, it illustrates the pricing environment that can affect biologic franchises over time.
ONC also faces intellectual-property risk. The USPTO invalidated all challenged claims of Pharmacyclics' U.S. Patent No. 11,672,803 in an April 29, 2025 post-grant review decision, and the decision was appealable. Patent litigation remains relevant because BRUKINSA is the company's largest commercial asset.
$4.55B in cash versus $1.10B of debt, plus a 3.4 current ratio and 0.25 debt-to-equity, gives ONC enough flexibility to fund its pipeline without leaning heavily on outside capital.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 revenue rose 30% to $1.7B and GAAP earnings per ADS jumped 144% to $2.05, while gross margin stayed just under 90% as expenses grew more slowly than sales.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 revenue guidance to $6.6B-$6.8B and GAAP operating income guidance to $1.0B-$1.1B after a quarter that beat on both growth and profitability.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →ONC trades at 73.9x trailing earnings and 47.8x forward earnings, a premium multiple that reflects BRUKINSA’s leadership but leaves little room for execution missteps.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s price framework spans $275 to $520, with $385 marking the fair value level that separates a Buy from a more cautious stance.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →ONC has crossed an important threshold: it is no longer valued solely as a promise. The company produced $5.34B of 2025 revenue, $286.9M of net income, $941.7M of free cash flow, and $3.45B of net cash. Q2 2026 then added 30% revenue growth, a 31% increase in BRUKINSA sales, and higher full-year guidance.
The next phase depends on whether ONC can extend that commercial momentum beyond its flagship product. TEVIMBRA growth, BEQALZI commercialization, MANGROVE, the BTK degrader, and solid-tumor programs provide several possible routes, but each carries clinical or execution risk.
For a medium-term investor, the combination of strong cash generation, global oncology scale, and a broad development pipeline outweighs the valuation risk at current levels. The appropriate stance is Buy with position sizing discipline, recognizing that ONC is a profitable growth company whose stock can still behave like biotechnology during clinical, regulatory, or geopolitical shocks.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
BeOne Medicines AG (ONC) gains after a deep earnings analysis of a broad Q2 beat, with EPS and revenue topping estimates, BRUKINSA driving growth, and raised 2026 guidance reinforcing the stock’s measured upside despite an already strong run.
BeOne Medicines AG (ONC) gains 2.6% after reporting earnings beats, lifting shares as investors react to stronger-than-expected results and improved outlook.
BeiGene has crossed from cash-burning biotech into a profitable global oncology platform, powered by BRUKINSA’s rapid growth and a strengthening balance sheet. The pipeline still matters, but the investment case now rests on commercial execution and self-funding momentum.